Hims & Hers Health (NYSE:HIMS) Price Target Raised to $16.00

Hims & Hers Health (NYSE:HIMS) had its price objective lifted by equities research analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 31.58% from the company’s previous close.

A number of other research firms have also recently commented on HIMS. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Guggenheim raised their price target on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. SVB Leerink initiated coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price for the company. Finally, Citigroup raised their price objective on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $15.07.

Hims & Hers Health Trading Down 1.5 %

Hims & Hers Health stock opened at $12.16 on Tuesday. The company has a fifty day simple moving average of $14.01 and a 200 day simple moving average of $10.39. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $17.16. The company has a market cap of $2.61 billion, a P/E ratio of -107.91 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.05) earnings per share. On average, equities research analysts forecast that Hims & Hers Health will post 0.11 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares in the company, valued at $494,835.74. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Soleil Boughton sold 63,621 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57. Following the completion of the transaction, the insider now directly owns 154,345 shares in the company, valued at approximately $2,341,413.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the sale, the chief executive officer now owns 51,653 shares in the company, valued at approximately $494,835.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 736,191 shares of company stock valued at $9,733,700. Company insiders own 31.63% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Entropy Technologies LP acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $1,386,000. ProShare Advisors LLC raised its stake in shares of Hims & Hers Health by 10.0% during the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after acquiring an additional 2,023 shares during the last quarter. Avantax Advisory Services Inc. bought a new stake in shares of Hims & Hers Health in the first quarter worth $156,000. Headlands Technologies LLC acquired a new stake in Hims & Hers Health in the first quarter valued at $228,000. Finally, Sei Investments Co. raised its position in Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.